Sponsor
Roche Products
111 PBAC submissions on file, active 2005–2025. 76% have been recommended.
Submissions
111
2005 → 2025
Win rate
76 %
84 recommended of 111 bucketable
Drugs
26 · 22 listed
unique molecules submitted
PBS spend captured
$749M
FY-latest govt benefit on owned drugs
Drug portfolio
Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.
Therapy area mix Oncology 58 Haematology 13 Rheumatology 13 Respiratory 7 Neurology 5 Ophthalmology 4 Rare disease 3 Infectious disease 2 Immunology 2 Women's health 2
Activity by year 2005 (2) · 2006 (5) · 2007 (3) · 2008 (4) · 2009 (2) · 2010 (5) · 2011 (5) · 2012 (4) · 2013 (6) · 2014 (7) · 2015 (8) · 2016 (8) · 2017 (9) · 2018 (7) · 2019 (12) · 2020 (7) · 2021 (2) · 2022 (4) · 2023 (1) · 2024 (3) · 2025 (7)
Rejection patterns
Across 18 Not recommended decisions on file.
1× insufficient long-term utilisation data (alectinib recently listed 1 January 2018)1× risk of inappropriately extending treatment duration with unclear impact on cost-effectiveness1× risk of leakage to other ALK-positive cancers lacking robust evidence of effectiveness and cost-effectiveness1× Authority Required (STREAMLINED) listing inappropriate until ALK-inhibitor market had stabilised1× re-modelling approaches overestimated incremental overall survival gain and incremental QALYs gainedOpen on full dashboard →
Part of script.report — an independent tracker of every PBAC Public Summary Document and the PBS expenditure that follows. Built from public data on pbs.gov.au . Not affiliated with the Australian Department of Health, PBAC, or any pharmaceutical company.
script.report extracts information discussed in PBAC Public Summary Documents (PSDs), not independently calculated values. Where figures such as ICERs are shown, they reflect what was discussed or referenced in committee documentation — not confirmed inputs. For authoritative cost-effectiveness data, refer to the original PSD.